Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josianne Nitcheu

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Expert Review of Vaccines|August 23, 2011
Outlining novel cellular adjuvant products for therapeutic vaccines against cancerJosianne Nitcheu Tefit, Vincent Serra
Methods in Molecular Biology (Clifton, N.J.)|January 26, 2010
NKT cell responses to glycolipid activationJosianne Nitcheu Tefit, Gwyn Davies, Vincent Serra
The Journal of Pathology|December 20, 2005
Bacterial gene therapy strategiesGeorges Vassaux, Josianne Nitcheu, Sarah Jezzard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2003
Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesisJosianne Nitcheu, Olivia Bonduelle, Christophe Combadiere, et al.
Molecular Cancer Therapeutics|October 5, 2022
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse ModelsDidier Scherrer, Noel Barrett, Luc Teyton, et al.
Vaccine|September 15, 2014
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccinationJosianne Nitcheu Tefit, Sandrine Crabé, Bernard Orlandini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivoJosianne Nitcheu-Tefit, Ming-Shen Dai, Rebecca J Critchley-Thorne, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumorsMing-Shen Dai, Josianne Nitcheu-Tefit, Sally Alcock, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.
The Journal of Infectious Diseases|June 13, 2018
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative PatientsChristoph Höner Zu Siederdissen, Aric Josun Hui, Wattana Sukeepaisarnjaroen, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Review of Vaccines|August 23, 2011
Outlining novel cellular adjuvant products for therapeutic vaccines against cancerJosianne Nitcheu Tefit, Vincent Serra
Methods in Molecular Biology (Clifton, N.J.)|January 26, 2010
NKT cell responses to glycolipid activationJosianne Nitcheu Tefit, Gwyn Davies, Vincent Serra
The Journal of Pathology|December 20, 2005
Bacterial gene therapy strategiesGeorges Vassaux, Josianne Nitcheu, Sarah Jezzard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2003
Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesisJosianne Nitcheu, Olivia Bonduelle, Christophe Combadiere, et al.
Molecular Cancer Therapeutics|October 5, 2022
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse ModelsDidier Scherrer, Noel Barrett, Luc Teyton, et al.
Vaccine|September 15, 2014
Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccinationJosianne Nitcheu Tefit, Sandrine Crabé, Bernard Orlandini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivoJosianne Nitcheu-Tefit, Ming-Shen Dai, Rebecca J Critchley-Thorne, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumorsMing-Shen Dai, Josianne Nitcheu-Tefit, Sally Alcock, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2022
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extensionSeverine Vermeire, Bruce E Sands, Herbert Tilg, et al.
The Journal of Infectious Diseases|June 13, 2018
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative PatientsChristoph Höner Zu Siederdissen, Aric Josun Hui, Wattana Sukeepaisarnjaroen, et al.
Pageof 2